论文部分内容阅读
目的 评价尿激酶 (UK)冠脉内与静脉溶栓治疗急性心肌梗死 (AMI)的临床疗效及安全性。方法 58例AMI患者随机分为冠脉溶栓组 (A组 )及静脉溶栓组 (B组 )各 2 9例 ,分别给予UK治疗。结果 心肌梗死相关血管再通率A组 82 .8%与B组 62 .1 %比较 ,P <0 .0 5。但出血并发症B组 1 0 .3%与A组 3 .5%相比较 ,P <0 .0 5。结论 冠脉内溶栓治疗AMI安全有效的 ,可明显改善病人近期、远期预后
Objective To evaluate the clinical efficacy and safety of urokinase (UK) intracoronary and intravenous thrombolysis in the treatment of acute myocardial infarction (AMI). Methods Fifty-eight patients with AMI were randomly divided into coronary thrombolysis group (A group) and intravenous thrombolysis group (B group), with 29 cases treated with UK respectively. Results Myocardial infarction related vascular recanalization rate of 82.8% in group A was 62.1% compared with that in group B, P <0.05. However, bleeding complications in group B were 0.3% compared with those in group A (3.5%), P <0.05. Conclusion Intra-coronary thrombolytic therapy for AMI is safe and effective, which can significantly improve the short-term and long-term prognosis of patients